Abstract
Burkholderia mallei, the etiologic agent of glanders, are Category B select agents with biothreat potential, and yet effective therapeutic treatments are lacking. In this study, we showed that CpG administration increased survival, demonstrating protection in the murine glanders model. Bacterial recovery from infected lungs, liver and spleen was significantly reduced in CpG-treated animals as compared with non-treated mice. Reciprocally, lungs of CpG-treated infected animals were infiltrated with higher levels of neutrophils and inflammatory monocytes, as compared to control animals. Employing the B. mallei bioluminescent strain CSM001 and the Neutrophil-Specific Fluorescent Imaging Agent, bacterial dissemination and neutrophil trafficking were monitored in real-time using multimodal in vivo whole body imaging techniques. CpG-treatment increased recruitment of neutrophils to the lungs and reduced bioluminescent bacteria, correlating with decreased bacterial burden and increased protection against acute murine glanders. Our results indicate that protection of CpG-treated animals was associated with recruitment of neutrophils prior to infection and demonstrated, for the first time, simultaneous real time in vivo imaging of neutrophils and bacteria. This study provides experimental evidencesupporting the importance of incorporating optimized in vivo imaging methods to monitor disease progression and to evaluate the efficacy of therapeutic treatment during bacterial infections.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 383-401 |
| Number of pages | 19 |
| Journal | Pathogens |
| Volume | 2 |
| Issue number | 2 |
| DOIs | |
| State | Published - May 23 2013 |
Fingerprint
Keywords
- Burkholderia mallei
- Cpg
- Immunomodulation
- In vivo imaging
- Infrared fluorescent imaging
ASJC Scopus subject areas
- Immunology and Microbiology(all)
- Infectious Diseases
- Microbiology (medical)
- Immunology and Allergy
- Molecular Biology
Cite this
Monitoring therapeutic treatments against Burkholderia infections using imaging techniques. / Mott, Tiffany M.; Johnston, R. Katie; Vijayakumar, Sudhamathi; Estes, D. Mark; Motamedi, Massoud; Sbrana, Elena; Endsley, Janice; Torres, Alfredo.
In: Pathogens, Vol. 2, No. 2, 23.05.2013, p. 383-401.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Monitoring therapeutic treatments against Burkholderia infections using imaging techniques
AU - Mott, Tiffany M.
AU - Johnston, R. Katie
AU - Vijayakumar, Sudhamathi
AU - Estes, D. Mark
AU - Motamedi, Massoud
AU - Sbrana, Elena
AU - Endsley, Janice
AU - Torres, Alfredo
PY - 2013/5/23
Y1 - 2013/5/23
N2 - Burkholderia mallei, the etiologic agent of glanders, are Category B select agents with biothreat potential, and yet effective therapeutic treatments are lacking. In this study, we showed that CpG administration increased survival, demonstrating protection in the murine glanders model. Bacterial recovery from infected lungs, liver and spleen was significantly reduced in CpG-treated animals as compared with non-treated mice. Reciprocally, lungs of CpG-treated infected animals were infiltrated with higher levels of neutrophils and inflammatory monocytes, as compared to control animals. Employing the B. mallei bioluminescent strain CSM001 and the Neutrophil-Specific Fluorescent Imaging Agent, bacterial dissemination and neutrophil trafficking were monitored in real-time using multimodal in vivo whole body imaging techniques. CpG-treatment increased recruitment of neutrophils to the lungs and reduced bioluminescent bacteria, correlating with decreased bacterial burden and increased protection against acute murine glanders. Our results indicate that protection of CpG-treated animals was associated with recruitment of neutrophils prior to infection and demonstrated, for the first time, simultaneous real time in vivo imaging of neutrophils and bacteria. This study provides experimental evidencesupporting the importance of incorporating optimized in vivo imaging methods to monitor disease progression and to evaluate the efficacy of therapeutic treatment during bacterial infections.
AB - Burkholderia mallei, the etiologic agent of glanders, are Category B select agents with biothreat potential, and yet effective therapeutic treatments are lacking. In this study, we showed that CpG administration increased survival, demonstrating protection in the murine glanders model. Bacterial recovery from infected lungs, liver and spleen was significantly reduced in CpG-treated animals as compared with non-treated mice. Reciprocally, lungs of CpG-treated infected animals were infiltrated with higher levels of neutrophils and inflammatory monocytes, as compared to control animals. Employing the B. mallei bioluminescent strain CSM001 and the Neutrophil-Specific Fluorescent Imaging Agent, bacterial dissemination and neutrophil trafficking were monitored in real-time using multimodal in vivo whole body imaging techniques. CpG-treatment increased recruitment of neutrophils to the lungs and reduced bioluminescent bacteria, correlating with decreased bacterial burden and increased protection against acute murine glanders. Our results indicate that protection of CpG-treated animals was associated with recruitment of neutrophils prior to infection and demonstrated, for the first time, simultaneous real time in vivo imaging of neutrophils and bacteria. This study provides experimental evidencesupporting the importance of incorporating optimized in vivo imaging methods to monitor disease progression and to evaluate the efficacy of therapeutic treatment during bacterial infections.
KW - Burkholderia mallei
KW - Cpg
KW - Immunomodulation
KW - In vivo imaging
KW - Infrared fluorescent imaging
UR - http://www.scopus.com/inward/record.url?scp=85015512510&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85015512510&partnerID=8YFLogxK
U2 - 10.3390/pathogens2020383
DO - 10.3390/pathogens2020383
M3 - Article
VL - 2
SP - 383
EP - 401
JO - Pathogens
JF - Pathogens
SN - 2076-0817
IS - 2
ER -